Wanting on the underlying holdings of the ETFs in our protection universe at ETF Channel, we’ve got in contrast the buying and selling value of every holding towards the common analyst 12-month ahead goal value, and computed the weighted common implied analyst goal value for the ETF itself. For the Invesco Dynamic Biotechnology & Genome ETF (Image: PBE), we discovered that the implied analyst goal value for the ETF primarily based upon its underlying holdings is $61.97 per unit.
With PBE buying and selling at a latest value close to $56.55 per unit, that implies that analysts see 9.58% upside for this ETF wanting by means of to the common analyst targets of the underlying holdings. Three of PBE’s underlying holdings with notable upside to their analyst goal costs are Enanta Prescribed drugs Inc (Image: ENTA), Corcept Therapeutics Inc (Image: CORT), and Bausch Well being Firms Inc (Image: BHC). Though ENTA has traded at a latest value of $64.55/share, the common analyst goal is 48.72% larger at $96.00/share. Equally, CORT has 21.16% upside from the latest share value of $12.65 if the common analyst goal value of $15.33/share is reached, and analysts on common are…